JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

Search

Crinetics Pharmaceuticals Inc

Deschisă

SectorSănătate

40.17 -0.94

Rezumat

Modificarea prețului

24h

Curent

Minim

39.79

Maxim

41.05

Indicatori cheie

By Trading Economics

Venit

-19M

-116M

Vânzări

670K

1M

Marjă de profit

-11,216.004

Angajați

437

EBITDA

-19M

-129M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+99.36% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.4B

4B

Deschiderea anterioară

41.11

Închiderea anterioară

40.17

Sentimentul știrilor

By Acuity

50%

50%

168 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 oct. 2025, 22:47 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 oct. 2025, 22:13 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 oct. 2025, 21:20 UTC

Câștiguri

Correction to IBM 3Q Sales Jump Article

22 oct. 2025, 20:57 UTC

Câștiguri

SAP Posts Higher 3Q Revenue, Operating Profit

22 oct. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 oct. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 oct. 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct. 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct. 2025, 23:15 UTC

Câștiguri

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 oct. 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 oct. 2025, 22:02 UTC

Câștiguri

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 oct. 2025, 21:59 UTC

Achiziții, Fuziuni, Preluări

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 oct. 2025, 21:58 UTC

Achiziții, Fuziuni, Preluări

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 oct. 2025, 21:57 UTC

Achiziții, Fuziuni, Preluări

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 oct. 2025, 21:56 UTC

Achiziții, Fuziuni, Preluări

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 oct. 2025, 21:47 UTC

Achiziții, Fuziuni, Preluări

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 oct. 2025, 21:47 UTC

Câștiguri

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct. 2025, 21:47 UTC

Achiziții, Fuziuni, Preluări

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 oct. 2025, 21:46 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 oct. 2025, 21:45 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 oct. 2025, 21:45 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 oct. 2025, 21:28 UTC

Market Talk
Câștiguri

Correction to Alcoa Tariff Market Talk

22 oct. 2025, 21:25 UTC

Câștiguri

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 oct. 2025, 21:17 UTC

Câștiguri

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 oct. 2025, 21:09 UTC

Market Talk
Câștiguri

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 oct. 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22 oct. 2025, 20:59 UTC

Câștiguri

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct. 2025, 20:51 UTC

Câștiguri

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 oct. 2025, 20:44 UTC

Câștiguri

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Comparație

Modificare preț

Crinetics Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

99.36% sus

Prognoză pe 12 luni

Medie 80.6 USD  99.36%

Maxim 143 USD

Minim 40 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCrinetics Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

16 ratings

15

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

30.39 / 33.46Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

168 / 371 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat